
A 779(3TFA)
CAS No. 159432-28-7
A 779(3TFA)( —— )
Catalog No. M21034 CAS No. 159432-28-7
A 779(3TFA) is a potent antagonist of angiotensin-(1-7) receptor?.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 56 | Get Quote |
![]() ![]() |
10MG | 83 | Get Quote |
![]() ![]() |
25MG | 150 | Get Quote |
![]() ![]() |
50MG | 225 | Get Quote |
![]() ![]() |
100MG | 338 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameA 779(3TFA)
-
NoteResearch use only, not for human use.
-
Brief DescriptionA 779(3TFA) is a potent antagonist of angiotensin-(1-7) receptor?.
-
DescriptionA 779(3TFA) is a potent antagonist of angiotensin-(1-7) receptor.
-
In VitroA-779 inhibits the effect of Ang-(1-7), which suppresses the proliferating cell nuclear antigen (PCNA) protein expression up-regulated by Ang II, but A-779 alone has no effect to induce proliferation and migration of VSMCs. Pretreatment with Ang-(1-7) significantly retards Ang II-induced inflammatory responses of VSMCs associated with up-regulated MCP-1, VCAM-1 and IL-1β expressions, and this effect of Ang-(1-7) is blocked by A-779. But A-779 alone has no effect to induce inflammatory response of VSMCs. Pretreatment VSMCs with Ang-(1-7) for 5?min significantly inhibits Akt and ERK1/2 phosphorylation induced by Ang II, and this effect is also blocked by A-779, but alone has no effect to induce phosphorylation of Akt and ERK1/2 in VSMCs.
-
In VivoInfusion of Ang(1-7) and A-779 (400ng/kg/min, s.c.) alone or combined for 6 weeks does not prevent uterus atrophy or inhibit the body weight gain of OVX rats. A-779 markedly elevates serum bone specific alkaline phosphatase (BALP), telopeptides of collagen type I (CTX), tartarate resistant acid phosphatase (TRAcP 5b), osteocalcin (OC) and urinary deoxypyridinoline (DPD). Infusion of Ang(1-7) and/or A-779 does not significantly change serum minerals concentrations in sham or OVX groups. A-779 in the OVX animals does not change AngII, Ang(1-7), AT1R, AT2R, ACE, ACE-2, Mas receptor, RANKL and OPG proteins expressions in relation to OVX group, while AngII (P0.05), AT1R (P0.05), ACE (P0.01) and RANKL (P0.01) expressions are significantly higher and Ang(1-7), AT2R, ACE-2, MasR and OPG are significantly (P0.01) lower than sham group. Blocking of the G-protein coupled receptor (Mas) by A-779 markedly abolishes Ang(1-7) favorable effects on bone health suggesting the vital role of Mas receptor in mediating Ang(1-7) osteo-protective effects. Inhibition of Ang1-7 cascade by A-779 (400ng/kg/min) significantly eradicates captopril protective effects on bone metabolism, mineralization and micro-structure. A-779 also restores OVX effects on RANKL expression and ACE-1/AngII/AT1R cascade and down-regulates OPG expression and ACE-2/Ang1-7/Mas pathway.
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetRAAS
-
RecptorAngiotensin Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number159432-28-7
-
Formula Weight872.97
-
Molecular FormulaC39H60N12O11
-
Purity>98% (HPLC)
-
SolubilityH2O:50 mg/mL (57.28 mM; Need ultrasonic)
-
SMILESCCC(C)C(NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(NC(=O)C(CCCNC(=N)N)NC(=O)C(N)CC(=O)O)C(C)C)C(=O)NC(Cc1cnc[nH]1)C(=O)NC(C)C(=O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yan W F Xue J J Yang H Y et al. [Effects and related mechanism of angiotensin-(1-7) on Toll-like receptor 4-mediated oxidative stress in human umbilical vein endothelial cells].[J]. Zhonghua Xin Xue Guan Bing Za Zhi 2017 45(3):223.
molnova catalog



related products
-
Ramiprilat
Ramiprilat is an angiotensin-converting enzyme (ACE) inhibitor?with antihypertensive activity.
-
Zofenopril (calcium)
Zofenopril Calcium(SQ26991) is an antioxidant that acts as an angiotensin-converting enzyme inhibitor. ACE Zofenopril is a pro-drug designed to undergo metabolic hydrolysis yielding the active free sulfhydryl compound zofenoprilat which is an angiotensin converting enzyme (ACE) inhibitor.
-
Ripisartan
Ripisartan (UP-269-6) is a potent and specific angiotensin II receptor antagonist that inhibits angiotensin II-mediated sympathetic tachycardia responses.